Rationale Indirect-acting serotonin (5-HT) receptor agonists (e.g., selective 5-HT reuptake inhibitors [SSRI]) stimulate multiple 5-HT receptors, although the role of particular receptors as well as interaction(s) among different receptors in the therapeutic effects of SSRIs is not fully understood.
Introduction
Selective serotonin (5-HT) reuptake inhibitors (SSRIs) are indirect-acting 5-HT receptor agonists insofar as they block the reuptake of 5-HT that can act at multiple receptor subtypes. Among 5-HT receptors it is thought that 5-HT 1A and 5-HT 2A receptors are particularly important for the therapeutic (e.g., antidepressant) effects of SSRIs (Celada et al. 2004 ). However, the actions of indirectacting agonists likely include interactions between activities at different 5-HT receptor subtypes. For example, the 5-HT 2A receptor antagonist (+)2,3-dimethoxyphenyl-1-[2-(4-piperidine)-methanol] (MDL100907) enhances the antidepressant-like activity of SSRIs in rats (Marek et al. 2005) , suggesting that activation of 5-HT 2A receptors might attenuate therapeutic effects of SSRIs that are mediated through other (e.g., 5-HT 1A ) receptors. The current study administered direct-acting 5-HT receptor agonists in combination to examine interactions that might be relevant to the therapeutic effects of indirect-acting 5-HT receptor agonists.
A number of studies have examined interactions between drugs that are thought to act at different 5-HT receptor subtypes. For example, the 5-HT 2A receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) increases the plasma concentrations of ACTH and this effect is enhanced by the 5-HT 1A receptor agonist 8-hydroxy-2-(din-propylamino) tetralin hydrochloride (8-OH-DPAT; Li et al. 1992) . Furthermore, 5-methoxy-dimethyltryptamine-induced head twitching (Darmani et al. 1989) , an effect that is thought to be mediated by 5-HT 2A receptor activation (Green et al. 1983) , is enhanced by the 5-HT 1A receptor agonist 8-OH-DPAT (Darmani et al. 1989 ). DOI increases 8-OH-DPAT-induced forepaw treading (Arnt and Hyttel 1989) ; on the other hand, DOI-induced head twitching is inhibited by 8-OH-DPAT (Darmani et al. 1989) . Some drugs that have agonist activity at 5-HT 1A receptors occasion some drugappropriate responding in rats discriminating a 5-HT 2A receptor agonist (1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane [DOM] or lysergic acid diethylamide) and when studied in combination the same 5-HT 1A receptor agonists enhance the discriminative stimulus effects of 5-HT 2A receptor agonists (Khorana et al. 2009; Reissig et al. 2005) . On the other hand, both 8-OH-DPAT and DOI decrease locomotion in rats and when the two drugs are administered together the interaction is infra-additive (Krebs-Thomson and Geyer 1998).
Interpretation of results from prior studies that examined interactions between 5-HT receptor agonists is, in some cases, limited by the following: (1) many 5-HT receptor agonists bind to and have activity at multiple receptor subtypes; (2) often antagonists are not used to confirm the receptor subtype through which a particular agonist produces a behavioral effect; (3) in some studies, particularly those examining elicited behavior, 5-HT 1A and 5-HT 2 receptor agonists can produce qualitatively different effects (under such conditions, apparent interactions between agonists that are thought to act at different receptor subtypes might reflect functional competition between incompatible behavioral effects and not pharmacodynamic interactions between agonist actions at different receptor subtypes); and (4) many studies have not analyzed behavioral data quantitatively and neither have they systematically varied the proportion of drugs studied in combination. For example, data from drug interaction studies often are presented as isobolograms which, although providing a visualization of results, are challenging to analyze statistically. The current study used a dose addition approach whereby different proportions of drugs were studied in combination and the empirically determined dose-response curves were compared with dose-response curves expected on the basis of additivity. As compared with isobolograms, the dose addition approach is more amenable to statistical analyses (Tallarida 2000) . It is important to systematically vary proportions in drug interactions studies because different proportions of the same drugs can yield markedly different results.
This study used schedule-controlled responding in rats to examine possible interactions between agonists that are thought to act selectively at either 5-HT 1A (3-chloro-4-fluorophenyl-(4-fluoro-4-{[(5-methyl-6-methylamino-pyridin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl-methanone fumaric acid salt [F13714] and 8-OH-DPAT)) or 5-HT 2A (DOM and DPT) receptors. Antagonists that are selective for 5-HT 1A (WAY100635) or 5-HT 2A (MDL100907) receptors were used to confirm the receptor(s) mediating the rate-decreasing effects of agonists. Subsequently, drugs acting at the same or different receptors were studied in combination to test whether their interaction was additive (as expected for drugs acting at the same receptor), infraadditive, or supra-additive. (Carter et al. 2003) . Data were collected using MED-PC IV software and an interface (MED Associates, Inc.). Rats were trained to press the right lever in multiple-cycle sessions conducted 7 days/week. Each cycle consisted of a 10-min pretreatment period when stimulus lights were not illuminated and responding had no scheduled consequence, followed by a 5-min response period when the light above the right lever was illuminated and rats could respond under a fixed ratio five schedule to receive a maximum of ten food pellets (45 mg; Research Diets, New Brunswick, NJ). When ten food pellets were delivered before 5 min had elapsed, the light was extinguished and responses had no programmed consequence for the remainder of the response period. Throughout the study, responses on the left lever had no programmed consequence. Daily training sessions consisted of 5 cycles and testing began after rats satisfied the following criteria for five consecutive sessions: the average response rate across sessions varied by less than ±20%; and the average response rate for all cycles within a session varied by less than ±20%. Test sessions were separated by at least two consecutive training sessions that satisfied these criteria.
Materials and methods

Subjects
During the first minute of each training cycle, rats received a vehicle or sham injection. Test sessions were identical to training sessions except that drug was administered. Doseresponse curves were determined using a cumulative-dosing procedure. During the first cycle, rats received vehicle; on subsequent cycles, rats received increasing doses of drug with the cumulative dose increasing by 0.5 log unit per cycle. For antagonism studies, an antagonist was administered 5 min before the start of the session. Testing continued until rats received fewer than five pellets in a cycle. Agonists were first studied alone, then with antagonists, and finally in combination.
Data analyses
Response rates were averaged among eight rats (±SEM) and plotted as a function of dose. In order to determine the potency of drugs to decrease responding, response rates were converted to percentages for individual subjects. Control response rates for individual rats were determined by averaging response rate across all cycles in a training (i.e., no drug) session; the mean rates for five sessions were averaged to obtain the overall control rate. Linear regression was used to estimate the dose required to decrease response rate to 50% of the control rate (ED 50 ) for individual rats. The 95% confidence limits (CL) were calculated from ED 50 values averaged among rats.
Interactions between agonists and antagonists were assessed using Schild analysis. Dose ratios were determined for each rat by dividing the ED 50 value for each agonist (8-OH-DPAT and DOM) studied in combination with an
and MDL100907) by the ED 50 value for the agonist studied alone (Li et al. 2009; Arunlakshana and Schild, 1959) . Schild plots were constructed by plotting the log of the dose ratio−1, as a function of the negative log dose of antagonist (expressed in moles per kilogram body weight). Straight lines were simultaneously fitted to the Schild plots using GraphPad Prism version 5.0 for Windows (GraphPad Software Inc., San Diego, CA) using the following equation: log dose ratio ð À 1Þ ¼ Àlog molar dose of antagonist ð Þ Â slope þ intercept; the apparent affinity (pA 2 ) values and 95% CLs with unconstrained slopes were determined. Slopes of Schild plots were considered to conform to unity when the 95% CL included −1 and did not include 0. For the agonist-antagonist combination studies that only studied one dose of antagonist, apparent pK B values were obtained using the equation: pK B ¼ Àlog molar ð of antagonist doseÞ= dose ratio À 1 ð Þ : Interactions between agonists were assessed using a fixed ratio dose addition analysis. For this analysis, two agonists were combined in a fixed proportion and administered using a cumulative dosing procedure. Dose-response curves for drugs administered alone and in combination were analyzed for parallelism with an F-ratio test (GraphPad Prism 5.0 for Windows; GraphPad Software, San Diego, CA; p<0.05). For drug mixtures, the dose-response curves were determined and the individual ED 50 values of the two drugs in the mixture were calculated based upon the shared dose-response curves. The sum of the ED 50 values of both drugs in the mixture was defined as Z mix . For statistical assessment of the drug interactions, the experimentally determined (observed) ED 50 values (Z mix ) were compared with the predicted additive ED 50 values (Z add ) as described previously (Tallarida 2000; Stevenson et al. 2005 ) and calculated using Pharm Tools Pro version 1.1 for Windows (The McCary Group Inc., Wilmington, DE). Z add values were determined for each rat from the following equation:
where A is the ED 50 for one drug alone in the mixture, B is the ED 50 for the other drug alone in the mixture, and f is the fractional multiplier of A in the computation of the additive total dose. The choice of f defines the proportion of drug A (ρ A ) in a mixture according to the following equation: r A ¼ fA=Z add . The present study examined the interaction of four drug combinations: 8-OH-DPAT and F13714; DOM and DPT; DOM and 8-OH-DPAT; and DOM and F13714. For each drug mixture the first drug was defined as drug A and the second drug was defined as drug B; these studies examined effects produced by drug mixtures in which f=0.25, 0.5, and 0.75. Thus, f = 0.25 leads to ρ A =A/(A+3B), and the ratio of drug A concentration to drug B concentration is [(A/ B)÷3]: 1; f=0.5 leads to ρ A =A/(A+B), and the ratio of drug A concentration to drug B concentration is (A/B): 1; and f= 0.75 leads to ρ A =3A/(3A+B), and the ratio of drug A concentration to drug B concentration is [(A/B) × 3]: 1. The Z add and Z mix values were calculated and the ratio Z mix /Z add was obtained for each individual subject. If the 95% CL of the mean of the ratio of the group did not include 1, then the ratio was considered to be significantly different from 1. A ratio significantly greater than 1 indicates that the drug mixture produces the effect in a manner that is less than additivity (infra-additivity); conversely, a ratio significantly smaller than 1 indicates that the drug mixture produces the effect in a manner that is significantly greater than additivity (supra-additivity).
Drugs
The compounds used in this study were dissolved in saline, unless otherwise noted, and included the following: DOM hydrochloride (NIDA Research Technology Branch, Rockville, MD); DPT hydrochloride and MDL100907 were synthesized by Kenner Rice (Ullrich and Rice 2000); 8-OH-DPAT was purchased from Sigma-Aldrich (St. Louis, MO); F13714 and WAY100635 were gifts from Dr. Adrian Newman-Tancredi (Centre de Recherche Pierre Fabre, Castres, France). MDL100907 was dissolved in 20% dimethylsulfoxide (v/v). Drugs were administered intraperitoneally and doses are expressed as the form indicated above in milligram per kilogram of body weight. Injection volumes were 0.2-1.0 ml.
Results
The average control response rate (±SEM) prior to the beginning of testing was 0.77±0.02 response/s. Response rates increased slightly, although not significantly, over the five cycles comprising daily sessions as follows: 0.73±0.07 in cycle 1; 0.75±0.05 in cycle 2; 0.79±0.06 in cycle 3; 0.76±0.07 in cycle 4; and 0.83±0.06 in cycle 5.
The 5-HT 1A receptor agonists F13714 and 8-OH-DPAT as well as the 5-HT 2A receptor agonists DOM and DPT decreased responding in a dose-related manner ( Fig. 1; see Table 1 for ED 50 values). The rank order potency for decreasing responding was F13714>8-OH-DPAT>DOM> DPT. The relative potency of each drug (in comparison with DPT; Table 1 ) was used to calculate the proportions of each drug used in drug mixtures for subsequent studies.
When administered alone, WAY100635 had no effect on responding (points above "V", left panels, Fig. 2) ; however, WAY100635 attenuated the rate-decreasing effect of 8-OH-DPAT with doses of 0.01, 0.032, and 0.1 mg/kg shifting the 8-OH-DPAT dose-response curve 2.4-, 6.9-, and 13.3-fold to the right, respectively (top left panel, Fig. 2 ). Schild analysis yielded a slope (95% CL) not different from −1 (−0.93 [−1.25, −0.71]) and a pA 2 value (95% CL) of 7.95 (7.62, 8.28; bottom left panel, Fig. 2 ). Similarly, a dose of 0.032 mg/kg WAY100907 attenuated the rate-decreasing effects of F13714, shifting the F13714 dose-response curve 4.6-fold to the right (middle left panel , Fig. 2) ; the apparent pK B for WAY100907 in attenuating F13714 was 7.78. A dose of 0.032 mg/kg of the selective 5-HT 2A receptor antagonist MDL100907 did not attenuate the ratedecreasing effect of 8-OH-DPAT (upper left panel, Fig. 2) .
When administered alone, MDL100907 did not significantly affect the rate of responding (points above "V", right panels, Fig. 2) ; however, MDL100907 attenuated the ratedecreasing effects of DOM with doses of 0.01, 0.032, and 0.1 mg/kg shifting the DOM dose-response curve 2.9-, 3.9-, and 4.5-fold to the right, respectively (upper right panel, Fig. 2 ). Schild analysis yielded a slope significantly Fig. 1 Effects of F13714, 8-OH-DPAT, DOM, and DPT on schedulecontrolled responding in rats. Abscissa, drug in milligrams per kilogram body weight. Ordinate, response rate in responses per second. All entries represent the mean (±SEM) from eight rats; entries above "V" represent response rate after vehicle administration Fig. 2 ). Slopes of dose-response curves for drug combinations were not significantly different from slopes of doseresponse curves for drugs administered alone (data not shown). Representative composite additive curves showing response rate as a function of the mixture dose for an individual rat (822) are shown in Fig. 3 for proportions of 1:3, 1:1, and 3:1 of 8-OH-DPAT and DOM. Comparison between expected (circles) and observed (squares) doseresponse curves indicate a difference (i.e., not additive) for a proportion of 3:1 but not for 1:3. Similar results were obtained in other rats (data not shown) and the mean ED 50 values for all drug mixtures are shown in Fig. 4) . In contrast, one combination of 8-OH-DPAT and DOM as well as two combinations of F13714 and DOM yielded ED 50 values that were significantly different from the expected (additive) values. As shown in Fig. 4 for a proportion of 3:1 of 8-OH-DPAT and a proportion of 1:1 and 3:1 of F13714 and DOM, the 95% CL for the ratio of the observed (Z mix ) and the expected (Z add ) ED 50 values did not include 1, indicating an infra-additive interaction. Other proportions of these mixtures were not different from the expected values.
Discussion
Indirect-acting 5-HT agonists (e.g., SSRIs) are used widely to treat various psychiatric disorders although the specific mechanism(s) accounting for the therapeutic effects of these drugs is not fully understood. For example, it is not clear Fig. 3 Composite additive curves from a representative rat for three mixtures (1:3, 1:1, and 3:1) of 8-OH-DPAT and DOM. Abscissae, log dose of the drug mixture in milligrams per kilogram body weight. Ordinate, response rate expressed as a percentage of the control (vehicle) rate However, the nature of the interaction between drugs can vary markedly depending on the relative activity (e.g., drug proportions in the mixture) at different receptor subtypes. Thus, the combined neuropharmacological actions and therapeutic effects of indirect-acting agonists are not likely to be adequately characterized by examining in isolation activity at particular 5-HT receptor subtypes. Prior studies that examined interactions between drugs acting selectively at different 5-HT receptor subtypes have often used experimental conditions where the two drugs of interest do not share the same effect; however, under such conditions interactions might be due to functional competition between incompatible behavioral effects and not to pharmacodynamic interactions. Similarly, the analysis and interpretation of interactions between agonists can be challenging when one of the drugs of interest is without effect when administered alone. Thus, there can be advantages to studying agonists that share a common effect, even if that effect occurs by actions at different receptors, because full dose-response curves can be determined for each agonist alone and for specific combinations (proportions) of two agonists. It is critical that the measured effects are mediated by the receptors of interest, particularly for agonists that are thought to have activity at more than one receptor. Many 5-HT receptor agonists have activity at more than one receptor subtype; for example, 8-OH-DPAT induced hypothermia in rats is mediated by both 5-HT 1A and 5-HT 7 receptors (Hedlund et al. 2004) . DOM has similar affinity for 5-HT 2A and 5-HT 2C receptors and reportedly exerts agonist activity at both receptor subtypes (Eckler et al. 2004; Fiorella et al. 1995; Li et al. 2009 ).
The current study used schedule-controlled responding to study interactions between drugs acting selectively at different 5-HT receptor subtypes because all of the drugs studied decrease responding in this procedure and they do so, at least in part, by actions at the receptor subtype of interest. Thus, the rate-decreasing effects of DOM and DPT (agonists at 5-HT 2A receptors), and not those of the selective 5-HT 1A receptor agonist F13714 (Koek et al. 2001) or 8-OH-DPAT (agonist at 5-HT 1A receptors), were attenuated by MDL100907 (selective 5-HT 2A receptor antagonist) and not by WAY100635 (selective 5-HT 1A receptor antagonist). Conversely, the rate-decreasing effects of F13714 and 8-OH-DPAT, and not those of DOM or DPT, were attenuated by WAY100635 and not by MDL100907. The apparent affinity estimate for WAY100635 in combination with 8-OH-DPAT in the current study was similar to apparent affinities reported by others for the same drugs (e.g., 7.8 [7.4, 8 .2]; Koek et al. 2000) and confirm the role of 5-HT 1A receptors. Moreover, the relative potency of the agonists in decreasing schedule-controlled responding was the same as their relative potency in other (e.g., drug discrimination) studies where it has been shown that they act selectively through a 5-HT receptor subtype (e.g., Li et al. 2010) . Thus, in the current study interactions between drugs were likely due to actions at 5-HT 1A and 5-HT 2A receptors because those are the receptor subtypes that mediate the ratedecreasing effects of the agonists studied.
Based on receptor theory, it was expected that the interaction between two agonists acting at the same 5-HT receptor subtype (either 5-HT 1A or 5-HT 2A ) would be additive. That is, when two drugs produce the same effect by acting at the same receptor, pretreatment with one drug should increase the effects of the second drug in an additive Abscissae, proportion ratios of each pair of the drug mixtures as indicated above each panel. * = ratio significantly (p<0.05) different from 1 manner. For example, in rats discriminating DOM, DPT enhances the discriminative stimulus effects of DOM in an additive manner (Li et al. 2010 ). In the current study, for drugs acting at the same receptor (as demonstrated by antagonism studies), the interaction for rate-decreasing effects was additive (i.e., between 8-OH-DPAT and F13714, on the one hand, and between DOM and DPT, on the other).
There are reports of non-additive (i.e., infra-or supraadditive) interactions between drugs acting at different 5-HT receptor subtypes (e.g., 5-HT 1A and 5-HT 2A ). The current study used a dose addition analysis to investigate interactions between agonists acting at different 5-HT receptor subtypes. The interactions between either 8-OH-DPAT or F13714 and DOM were additive or infra-additive, depending on the proportion of each drug in the mixture. When a smaller proportion of 8-OH-DPAT and F13714 was used in the drug mixture, their interaction with DOM was additive; however, when the proportion of 8-OH-DPAT and F13714 in the mixture was increased, their interaction with DOM was infra-additive. These results extend previous reports (Krebs- Thomson and Geyer 1998; Tallarida 2000) showing that the interaction between two drugs can vary significantly depending on the proportion of each drug in the mixture. It is unclear why interactions between agonists vary according to the relative activity at different receptors, although this would appear to be a fundamentally important area of research for understanding the in vivo actions of drugs that simultaneously activate more than one receptor (e.g., indirect-acting agonists).
In summary, this study used schedule-controlled responding in rats and quantitative pharmacological analyses to examine interactions between drugs acting selectively at 5-HT 1A or 5-HT 2A receptors. Antagonism studies confirmed that the rate-decreasing effects of 8-OH-DPAT and DOM are mediated predominantly, if not exclusively, by 5-HT 1A and 5-HT 2A receptors, respectively, and dose addition analyses showed that, depending on the relative proportion of drugs in the mixture, the interaction between 5-HT 1A and 5-HT 2A receptor agonists is additive or infra-additive. These data suggest that the neuropharmacology of indirect-acting 5-HT receptor agonists (e.g., SSRIs) includes possibly complex interactions between activities at different receptor subtypes and, therefore, that the therapeutic effects of such drugs cannot be fully understood by examining in isolation agonism at specific receptor subtypes.
